

Enclosure No:	1/AWMSG/0423
Agenda Item No:	1 – Minutes of previous meeting
Author:	Chair, AWMSG
Contact:	Tel: 029 218 26900 E-Mail: awttc@wales.nhs.uk

All Wales Medicines Strategy Group (AWMSG)

Draft minutes of the AWMSG meeting held at 9.30 am on Tuesday 7 March 2023 via Zoom

Voting members present:

**Did not
participate in
agenda item:**

- | | |
|---------------------------------|---|
| 1. Prof Iolo Doull | Chairman |
| 2. Prof Stephen Monaghan | Consultant in Public Health Medicine |
| 3. Dr Sian Lewis | Welsh Health Specialised Services
Commission |
| 4. Prof Dyfrig Hughes | Health Economist |
| 5. Mrs Claire James | Lay Representative |
| 6. Dr Richard Skone | Medical Director |
| 7. Dr Jeremy Black | GP with prescribing lead role |
| 8. Miss Rafia Jamil | Managed Sector Pharmacist |
| 9. Mr Stuart Rees | Managed Sector Pharmacist |
| 10. Mr Hywel Pullen | Director of Finance |
| 11. Mrs Mandy James | Senior Nurse |
| 12. Dr Alison Thomas | Clinical Pharmacologist |
| 13. Dr Sam Cox | Hospital Consultant |

AWTTC staff:

Mr Trevor Brooking, Administration Manager
Mr Richard Boldero, Senior Pharmacist
Dr Thomas Curran, Principal Scientist
Dr Stephanie Francis, Principal Scientist
Mr David Haines, Medical Writer
Mrs Ruth Lang, Senior Liaison Manager
Mr Anthony Williams, Head of PAMS

List of abbreviations:

ABPI	Association of the British Pharmaceutical Industry
ASAR	AWMSG Secretariat Assessment Report
ATMP	Advanced Therapy Medicinal Product
AWMSG	All Wales Medicines Strategy Group
AWPAG	All Wales Prescribing Advisory Group
AWTTC	All Wales Therapeutics & Toxicology Centre
BMA	British Medical Association
CAPIG	Clinical and Patient Involvement Group
CEPP	Clinical Effectiveness Prescribing Programme
CHMP	Committee for Medicinal Products for Human Use
DHCW	Digital Health and Care Wales
DoH	Department of Health
EMA	European Medicines Agency
EMIG	Ethical Medicines Industry Group
EOL	End of life
FAR	Final Appraisal Recommendation
FDA	US Food and Drug Administration
GP	General Practitioner
HAC	High Acquisition Cost
HB	Health Board
HEIW	Health Education and Improvement Wales
HST	Highly Specialised Technology
HTA	Health Technology Assessment
ILAP	Innovative Licensing and Access Pathway
IR	Independent Review
MHRA	Medicines and Healthcare products Regulatory Agency
M&TC	Medicines & Therapeutics Committee
NICE	National Institute for Health and Care Excellence
NMG	New Medicines Group
NPI	National Prescribing Indicator
OWMAG	One Wales Medicines Assessment Group
PAMS	Patient Access to Medicines Service
PAR	Preliminary Appraisal Recommendation
PAS	Patient Access Scheme
PPRS	Prescription Price Regulation Scheme
QAIF	Quality Assurance and Improvement Framework
RCGP	Royal College of General Practitioners
SABA	Short-acting beta agonist
SMC	Scottish Medicines Consortium
SPC	Summary of Product Characteristics
SPIRA	Server for Prescribing Information Reporting and Analysis
TDAPG	Therapeutic Development Appraisal Partnership Group
T&FG	Task and Finish Group
UHB	University Health Board
WAPSU	Welsh Analytical Prescribing Support Unit
WeMeReC	Welsh Medicines Resource Centre
WG	Welsh Government
WHO	World Health Organization
WHSSC	Welsh Health Specialised Services Committee
WPAS	Wales Patient Access Scheme

1. Welcome and introduction

The Chair opened the meeting, welcomed members and observers, and explained the meeting protocol.

2. Apologies:

Dr Helen Fardy, Welsh Health Specialised Services Commission
Mr Karl Jackson, Other healthcare professions eligible to prescribe
Ms Cathy Wynne, Other healthcare professions eligible to prescribe
Mr Tommy Price, ABPI (Wales)
Mr Andrew Evans, Welsh Government (non-voting member)

3. Declarations of interest:

The Chair invited declarations of interest. There were none.

4. Minutes of previous meeting

The draft minutes of the previous meeting held on 8 February 2023 were checked for accuracy.

The Chair asked members to approve an amendment to the minutes on Page 5 Minute 8 – Polypharmacy guidance Review - 2nd paragraph - to read “when patient information leaflets are available, they should also be available in Easy Read format for people who may have additional learning needs. The availability of Easy Read leaflets should also be properly noted (at 5.2) in the Equality Health Impact Assessment (EQHIA) in order to comply with the Equality Act 2010.

Matters arising:

Agenda item 6 - Electronic prescribing

Action - AWMSG to nominate a representative for the Shared Medicines Record Project group

Nomination: Dr Robert Bracchi (AWTTC)

Agenda item 10 – National prescribing indicators

Action - AWTTC to consider ways to continue to share good practice.

Update: To discuss at AWPAG on 15th March

Members agreed the change of wording and no other issues were raised.

The Chair confirmed approval of the minutes subject to the amendment.

5. Chairman's Report

The Chair thanked Dyfrig Hughes for chairing the previous AWMSG meeting. It was confirmed that Dyfrig Hughes will take on the role of Vice Chair going forward. Members confirmed their support.

The Chair thanked Karen Samuels and Kath Haines for their work, and mentioned that Karen and Kath may continue to provide some support to AWTTC in the interim until their positions are filled.

The Chair confirmed that AWMSG's advice for Sofosbuvir/velpatasvir (Epclusa®) has been ratified by Welsh Government and published on the AWMSG website.

6. **AWMSG Constitution**

The Chair invited members to review the AWMSG Constitution and consider the proposal for a chief pharmacist representative to be added to the membership. Members agreed and it was noted that the quoracy would increase from 9 to 10. The point was made that from April 2023, the new Citizen Voice Body (CVB) will replace the Community Health Councils to represent the voice of patients. It was agreed that the constitution review date should be changed to 1st April 2023 and Citizen Voice Body should replace Community Health Councils.

Action:

AWTTC to update the Constitution and submit to Welsh Government for approval

7. **NHS Wales inhaler carbon footprint report Nov 22**

Mr Richard Boldero presented the inhaler carbon footprint report for data to November 2022 and highlighted some of the main changes. Members were informed that there is now a full twelve months' worth of publicly available monthly reports on the AWTTC website. Members were asked for feedback or suggestions on how the report could be improved. There was discussion on how to present the data in the reports to best display positive trends in decarbonisation and avoid seasonal changes taking precedence. Mr Boldero said this would be looked into.

The Chair questioned whether or not anaesthetic gases should be included in the decarbonisation dataset. There was discussion about the role of AWMSG with regards to anaesthetic gases and members expressed caution about duplication of work with other groups looking at these. The Chair thanked members for their comments and confirmed that AWTTC would investigate a potential role for AWMSG in relation to anaesthetic gases.

8. **AWMSG Medicines Strategy 2023-2028**

The Chair informed members that an overview of the strategy would be presented by AWTTC and, following the meeting, members should remain online for more detailed informal discussions and to plan the way forward for the development of the document.

Mr Tom Curran presented an outline of the AWMSG Medicines Strategy 2023-2028, updating members on what had been discussed at the previous meeting, and the current proposed scope and structure of the strategy incorporating feedback from Welsh Government. Proposed timelines were presented. He highlighted the issues that would be discussed in the closed session and confirmed that further updates would be provided at subsequent meetings.

Any other business

There was no other business.

The Chair confirmed the next meeting will be held face-to-face on Wednesday, 19th April 2023 at the All Nations Centre in Cardiff and closed the meeting.